

06 April 2022 EMA/128682/2022 EMEA/H/W/003799

Public statement

Umbipro

Withdrawal of the scientific opinion under Article 58

GlaxoSmithKline Trading Services Limited has requested the European Medicines Agency to withdraw its scientific opinion for Umbipro (chlorhexidine).

Umbipro was evaluated by EMA under the Article 58 provision,¹ whereby EMA's Committee for Medicinal Products for Human Use (CHMP), in cooperation with the World Health organization (WHO), gives scientific opinions on medicines intended for use outside the European Union (EU).

The CHMP gave a positive opinion on Umbipro in April 2016.

The decision to request the withdrawal was based on commercial considerations.

Following the decision of GlaxoSmithKline Trading Services Limited, the scientific opinion for Umbipro will no longer be updated and the CHMP will make no further recommendations on its conditions of use.

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands **Address for visits and deliveries** Refer to www.ema.europa.eu/how-to-find-us **Send us a question** Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000



An agency of the European Union

 \odot European Medicines Agency, 2022. Reproduction is authorised provided the source is acknowledged.

¹ Regulation (EC) No 726/2004